六字诀呼吸操对老年慢性阻塞性肺疾病稳定期患者的疗效评估OA

Objective To investigate the efficacy of Liuzijue breathing exercises in elderly patients with stable chronic obstructive pulmo-nary disease(COPD).Methods Randomized controlled trial was conducted to randomly divide elderly patients with stable COPD into Liuzijue treatment group,respiratory function exercise and control group.TCM Liuzijue breathing exercise for 30 minutes each time,once a day.Respiratory function exercises include pursed lip breathing exercises and abdominal breathing exercises,each 15 minutes,a total of 30 minutes,once a day,and the control group was treated with conventional drugs only.The pulmonary function indexes of the three groups before treatment and 24 weeks after treatment were recorded,Modified Medical British Research Council(mMRC)respiratory questionnaire and COPD assessment test(CAT),clinical COPD questionnaire(CCQ),body mass index,airflow obstruction,dyspnea,and exercise capacity index(BODE),partial pressure of arterial oxygen(PaO2),and arterial partial pressure of carbon dioxide(PaCO2),the number of exacerbations within 24 weeks and the time to survive without exacerbations(weeks),Whether there was any statistical dif-ference between the three groups of the above indicators was compared.Results There were significant differences in FEV1,FEV1/FVC％,FEV1/pre％,mMRC,CAT,CCQ,BODE between the Liuziji treatment group and the respiratory exercise group and the control group after treatment(P<0.05),and there were no significant differences in PEF,PaO2 and PaCO2 between the three groups before and af-ter treatment(P>0.05).After 24 weeks of follow-up,it was found that the number of acute exacerbations in the Liuzijue treatment group was significantly lower than that in the respiratory function exercise group and the control group(P<0.01),and the survival time(weeks)withoutacute exacerbation in the Liuzijue treatment group was significantly better than that in the respiratory exercise group and the con-trol group(P<0.01).Conclusion Liuzijue breathing exercises can significantly improve the pulmonary function airflow limitation index and symptom score,improve the quality of life,and reduce the number of acute exacerbations in elderly patients with stable COPD.